Metastatic Kras G12c-Mutant Solid Tumor

In this video, Hossein Borghaei, DO, MS, discusses safety, response and survival data of patients with small cell lung cancer who received tarlatamab, a half-life extended bispecific T-cell engager, or HLE BiTE.

In this video, Jia Luo, MD, discusses two presentations from International Association for the Study of Lung Cancer World Conference on Lung Cancer investigating treatments for KRAS G12C lung cancer.

In this video, Ravi Salgia, MD, PhD, discussed findings from two studies presented at ASCO Annual Meeting — one investigating immunotherapy and the other targeted therapy — for the treatment of lung cancer.

In this video, Jia Luo, MD, spoke with Healio about an educational session she chaired at ASCO Annual Meeting.

Adagrasib induced promising clinical activity as monotherapy among pretreated patients with unresectable or metastatic pancreatic cancer and other gastrointestinal tumors that harbor a KRAS G12C mutation, according to study results.

Adagrasib induced promising clinical activity as monotherapy among pretreated patients with unresectable or metastatic pancreatic cancer and other gastrointestinal tumors that harbor a KRAS G12C mutation, according to study results.

Healio spoke with Sonam Puri, MD, about the CodeBreak100 trial presented at this year’s virtual annual ASCO meeting.

In this video, Pasi A. Jänne, MD, PhD, discussed updated data from the phase 2 CodeBreak100 trial presented at the virtual ASCO Annual Meeting.